| abstract |
The present invention relates to prodrugs 3 - ({3- (4-chlorophenyl) -5-oxo-4 - [(2S) -3,3,3-trifluoro-2-hydroxypropyl] -4,5-dihydro-1H -1,2,4-triazol-1-yl} methyl) -1- [3- (trifluoromethyl) -pyridin-2-yl] -1H-1,2,4-triazole-5-carboxamide, 3 - ({ 3- (4-chlorophenyl) -5-oxo-4 - [(2S) -3,3,3-trifluoro-2-hydroxypropyl] -4,5-dihydro-1H-1,2,4-triazole-1- yl} methyl) -1- [2- (trifluoromethyl) -phenyl] -1H-1,2,4-triazole-5-carboxamide and 3 - ({3- (4-chlorophenyl) -5-oxo-4- [ (2S) -3,3,3-trifluoro-2-hydroxypropyl] -4,5-dihydro-1H-1,2,4-triazol-1-yl} methyl) -1- (3-chloropyridin-2-yl ) -1H-1,2,4-triazole-5-carboxamide, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and / or prevention of diseases , in particular for the treatment and / or prevention of kidney and cardiovascular diseases. |